216 related articles for article (PubMed ID: 25343452)
1. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.
Nozaki K; Kagamu H; Shoji S; Igarashi N; Ohtsubo A; Okajima M; Miura S; Watanabe S; Yoshizawa H; Narita I
PLoS One; 2014; 9(10):e111019. PubMed ID: 25343452
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
3. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
5. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition.
Wang CY; Lee MH; Kao YR; Hsiao SH; Hong SY; Wu CW
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119016. PubMed ID: 33744274
[TBL] [Abstract][Full Text] [Related]
6. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
Bai XY; Zhang XC; Yang SQ; An SJ; Chen ZH; Su J; Xie Z; Gou LY; Wu YL
PLoS One; 2016; 11(3):e0149370. PubMed ID: 26943330
[TBL] [Abstract][Full Text] [Related]
7. Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.
Arasada RR; Shilo K; Yamada T; Zhang J; Yano S; Ghanem R; Wang W; Takeuchi S; Fukuda K; Katakami N; Tomii K; Ogushi F; Nishioka Y; Talabere T; Misra S; Duan W; Fadda P; Rahman MA; Nana-Sinkam P; Evans J; Amann J; Tchekneva EE; Dikov MM; Carbone DP
Nat Commun; 2018 Aug; 9(1):3198. PubMed ID: 30097569
[TBL] [Abstract][Full Text] [Related]
8. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789
[TBL] [Abstract][Full Text] [Related]
9. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Segura-Carretero A; Joven J; Martin-Castillo B; Barrajón-Catalán E; Micol V; Bosch-Barrera J; Menendez JA
Cell Cycle; 2013 Nov; 12(21):3390-404. PubMed ID: 24047698
[TBL] [Abstract][Full Text] [Related]
10. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y
Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
13. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
14. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
15. Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
Lee AF; Chen MC; Chen CJ; Yang CJ; Huang MS; Liu YP
PLoS One; 2017; 12(7):e0180383. PubMed ID: 28683123
[TBL] [Abstract][Full Text] [Related]
16. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
17. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Tabara K; Kanda R; Sonoda K; Kubo T; Murakami Y; Kawahara A; Azuma K; Abe H; Kage M; Yoshinaga A; Tahira T; Hayashi K; Arao T; Nishio K; Rosell R; Kuwano M; Ono M
PLoS One; 2012; 7(7):e41017. PubMed ID: 22815900
[TBL] [Abstract][Full Text] [Related]
18. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
19. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
20. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]